AstraZeneca to take rights to Dizal's lung cancer pill Zegfrovy

July 14, 2026 06:38 AM EDT DealsChinaPharma As­traZeneca to take rights to Diza­l's lung can­cer pill for $600M up­front Elizabeth Cairns Senior biopharma journalist As­traZeneca is set to pay Dizal Phar­ma­ceu­ti­cal, which it part-owns, $600 mil­lion up­front for world­wide de­vel­op­ment and sales rights to the lung can­cer drug Zegfrovy. … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER